You are here: Industry Insights > AbbVie

News List

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results americanpharmaceuticalreview
January 29, 2018
2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie
AbbVie Scores Key Trial Win for RA Drug With One Fatal Event Reported biospace
December 21, 2017
AbbVie’s investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients. But the drug shows that it is still plagued by some safety concerns.
AbbVie, Pfizer Jump in on Newly-Launched Jnana Therapeutics' $50M Funding Round biospace
December 18, 2017
Jnana Therapeutics launched with a $50 million Series A financing yesterday. Seed funders Polaris Partners and Avalon Ventures were joined in the round by Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst fiercepharma
December 07, 2017
The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way, one analyst says.
AbbVie’s psoriasis drug smashes all endpoints pharmafile
October 27, 2017
AbbVie already know well what it’s like to have a lead candidate in the psoriasis field, after having Humira sat at the top of the heap for years.
AbbVie plows $205M upfront Into Alector's Alzheimer's Program biospectrumasia
October 26, 2017
AbbVie Plows $205M Upfront Into Alector's Alzheimer's Program Under the terms of the deal, the two companies will research a portfolio of antibody targets.
AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology worldpharmanews
October 17, 2017
AbbVie ，a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, have announced a research
AbbVie obtains licence for Turnstone Biologics’ oncolytic viral immunotherapies pharmaceufical-technology
October 13, 2017
Under the deal, AbbVie has obtained an exclusive option to licence up to three of Turnstone's latest oncolytic viral immunotherapies.
AbbVie bags option on Turnstone oncolytic virus candidates fiercebiotech
October 11, 2017
AbbVie has secured an option on three of Turnstone Biologics’ oncolytic viral immunotherapies. The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once data from two ongoing phase 1/2 trials are available.
AbbVie’s Venclyxto now available through CDF pharmatimes
October 10, 2017
AbbVie's Venclyxto is now available through the Cancer Drug Foundation to patients with refractory chronic lymphocytic leukemia (CLL) form.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page